Pancreatic Cancer Research

ResearcherUniversity of Nebraska–LincolnActive in the last 2 years

Venugopal Gunda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9156-2580; OpenAlex author ID A5041700915. Sources: OpenAlex.

Their work

Papers
18 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
63
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 5 papers · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: none · 2025: 2 papers

Papers 18

  1. Niclosamide-Loaded Polyanhydride Nanoparticles to Combat Gemcitabine Resistance in Pancreatic Cancer. First author DOI 10.1007/s40883-025-00394-0↗
  2. Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition. First author DOI 10.1016/j.isci.2025.114088↗
  3. CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. Co-author DOI 10.1038/s41388-021-02132-6↗
  4. Ubiquitous Aberration in Cholesterol Metabolism across Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/metabo12010047↗
  5. Nuclear factor kappa-B contributes to cigarette smoke tolerance in pancreatic ductal adenocarcinoma through cysteine metabolism. Co-author DOI 10.1016/j.biopha.2021.112312↗
  6. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-020-0947-8↗
  7. Evaluating the Metabolic Alterations in Pancreatic Cancer. Co-author DOI 10.1007/978-1-4939-8879-2_20↗
  8. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-019-0368-8↗
  9. Metabolic Alterations in Pancreatic Cancer Progression. Co-author DOI 10.3390/cancers12010002↗
  10. Hypoxia-Induced Metabolomic Alterations in Pancreatic Cancer Cells. Co-author DOI 10.1007/978-1-4939-7665-2_9↗
  11. GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells. First author DOI 10.1016/j.canlet.2017.04.029↗
  12. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.06.004↗
  13. Glucose Limitation Alters Glutamine Metabolism in MUC1-Overexpressing Pancreatic Cancer Cells. Co-author DOI 10.1021/acs.jproteome.7b00246↗
  14. De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-3062↗
  15. MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-1151↗
  16. MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. First author DOI 10.18632/oncotarget.4078↗
  17. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Co-author DOI 10.18632/oncotarget.5843↗
  18. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Co-author DOI 10.1186/2049-3002-2-18↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pankaj Kumar Singh · 14 shared papers, 2014–2022 · strength 1.01
  2. Surinder K. Batra · 5 shared papers, 2015–2025 · strength 0.81
  3. Satyanarayana Rachagani · 4 shared papers, 2021–2025 · strength 0.76
  4. Surendra Kumar Shukla · 11 shared papers, 2014–2022 · strength 0.75
  5. Nina V. Chaika · 11 shared papers, 2014–2022 · strength 0.70
  6. Aneesha Dasgupta · 8 shared papers, 2015–2022 · strength 0.66
  7. Nagabhishek Sirpu Natesh · 3 shared papers, 2021–2025 · strength 0.62
  8. Jaime Abrego · 8 shared papers, 2015–2022 · strength 0.55
  9. Ryan J. King · 7 shared papers, 2015–2022 · strength 0.52
  10. Balaji Narasimhan · 2 shared papers, 2025 · strength 0.49
  11. Brianna M. White · 2 shared papers, 2025 · strength 0.49
  12. Susheel Kumar Nethi · 2 shared papers, 2025 · strength 0.49
  13. Enza Vernucci · 7 shared papers, 2015–2022 · strength 0.48
  14. Paul M. Grandgenett · 3 shared papers, 2017–2022 · strength 0.31
  15. Divya Murthy · 3 shared papers, 2017–2022 · strength 0.23
  16. Scott E. Mulder · 2 shared papers, 2017–2022 · strength 0.19
  17. Costas Andreas Lyssiotis · 3 shared papers, 2017–2020 · strength 0.18
  18. Michael Anthony Hollingsworth · 2 shared papers, 2017–2022 · strength 0.16
  19. Kuldeep Singh Attri · 2 shared papers, 2017–2022 · strength 0.16
  20. Vinee Purohit · 3 shared papers, 2014–2017 · strength 0.15
  21. Robert Powers · 3 shared papers, 2014–2017 · strength 0.15
  22. Teklab Gebregiworgis · 3 shared papers, 2014–2017 · strength 0.15
  23. Joshua J. Souchek · 3 shared papers, 2015–2017 · strength 0.15
  24. Ramakanth Chirravuri‐Venkata · 1 shared paper, 2022 · strength 0.15
  25. Jyoti Kaushal · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.